FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a pharmaceutical company with a significant focus on infectious diseases, announced today the expanded leadership roles of executive vice president Nathan McCutcheon and senior vice president Gianine Esposito.
Mr. McCutcheon has been appointed to the newly created position of chief operating officer. In his new role, Mr. McCutcheon will be responsible for achieving the company’s annual financial targets and leading all commercial operations, distribution and business development activities.
“Nate has been an influential leader since joining Shionogi, building a top-tier commercial organization to help us achieve our objectives,” said Akira Kato, Ph.D., President and CEO at Shionogi Inc. “It is our vision to build our U.S. business into a major contributor of value for Shionogi globally. This requires significant business development efforts to accelerate our near to mid-term inorganic growth while solidifying our commitment to helping patients in the field of infectious diseases. Nate’s career experience both strategically and operationally are well aligned with our growth opportunities for Shionogi U.S.”
Ms. Esposito, senior vice president, human resources, will join the Shionogi Inc. Executive Committee. In her current role, she is responsible for all aspects of human resources, corporate development and communications.
“I am pleased to welcome Gianine to the Executive Committee to help guide our company through the next level of growth,” said Dr. Kato. “She is a seasoned human resources leader who will bring a valuable perspective as we develop our talent and advance our business in the U.S.”
Mr. McCutcheon, who brings more than 20 years of commercialization experience in large, mid-sized and start-up pharmaceutical companies to his new role, joined Shionogi in 2019 as chief commercial officer and Executive Committee member. In his previous positions, he has served as general manager of multiple business units, led numerous product launches and has held roles in both global and U.S. capacities. McCutcheon has held leadership roles at Mallinckrodt, Allergan and Eli Lilly, among others. Mr. McCutcheon earned his M.B.A. from the Kelley School of Business, and a Bachelor of Science from Ball State University.
Ms. Esposito joined Shionogi in 2011 and assumed her position as senior vice president, human resources, in April 2020. With a 20-year career in human resources, she has held various leadership roles for companies, including Ferring Pharmaceuticals, GlaxoSmithKline, Liz Claiborne, Inc. and Gap Inc. Ms. Esposito received a Bachelor of Arts in English from the University of Connecticut.
Shionogi & Co., Ltd. is a major Japanese research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.”
Shionogi Inc., the U.S. subsidiary, currently holds the rights to products in several therapeutic areas with a specific commercialization focus on anti-infectives within the hospital. With the recent successful launch of FETROJA® (cefiderocol), Shionogi Inc. is positioned for growth by expanding its portfolio through business development efforts aligned with infectious disease/hospital promotion and our pipeline. Shionogi Inc. is based in N.J.
Forward Looking Statement
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also, for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.